Coronary Sinus Reducer for Treatment of Refractory Angina - COSIRA
This study is currently recruiting participants.
Verified November 2012 by Neovasc Inc.
Sponsor:
Neovasc Inc.
Information provided by (Responsible Party):
Neovasc Inc.
ClinicalTrials.gov Identifier:
NCT01205893
First received: September 13, 2010
Last updated: November 14, 2012
Last verified: November 2012
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to determine if the Reducer is safe and effective in treating the symptoms of refractory angina in patients that suffer from refractory angina who demonstrate reversible ischemia.
| Condition | Intervention | Phase |
|---|---|---|
|
Refractory Angina |
Device: Neovasc Reducer Device: Control |
Phase 2 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Outcomes Assessor) Primary Purpose: Treatment |
| Official Title: | Study to Confirm the Safety and Efficacy of the Reducer on Patients With Refractory Angina |
Resource links provided by NLM:
Further study details as provided by Neovasc Inc.:
Primary Outcome Measures:
- Canadian Cardiovascular Society Angina Score [ Time Frame: 6 months ] [ Designated as safety issue: No ]A decrease of two or more Canadian Cardiovascular Society Angina Score grades from baseline to six-month post-procedural evaluation in Reducer and Control groups
Secondary Outcome Measures:
- Technical success [ Time Frame: 24 hours ] [ Designated as safety issue: Yes ]Successful delivery and deployment of the Reducer to the intended site as assessed by the investigator
- Procedural success [ Time Frame: 24 hours ] [ Designated as safety issue: Yes ]Technical success and the absence of acute need for clinically-driven intervention to address an Adverse or Serious Adverse Device Effect prior to hospital discharge
- Periprocedural Serious Adverse Event: [ Time Frame: 30 days ] [ Designated as safety issue: Yes ]A composite of death, myocardial infarction, cardiac tamponade, clinically-driven re-dilation of a failed Reducer, life-threatening arrhythmia, and respiratory failure through 30 days post-procedure in the Reducer group.
- Periprocedural Serious Adverse Event [ Time Frame: 30 days ] [ Designated as safety issue: Yes ]A composite of death, myocardial infarction, cardiac tamponade, life-threatening arrhythmia, and respiratory failure through 30 days post-procedure in the control group.
- Major Adverse Events [ Time Frame: 6 months ] [ Designated as safety issue: Yes ]A composite of cardiac death, major stroke, and myocardial infarction in the Reducer and Control groups through hospital discharge, and at six-month post-procedural evaluations.
- Canadian Cardiovascular Society Angina Score [ Time Frame: 6 months ] [ Designated as safety issue: No ]A decrease one or more Canadian Cardiovascular Society Angina Score grades from baseline to six-month post-procedural evaluation in Reducer and Control groups
- Dobutamine Echo Wall Motion Score Index [ Time Frame: 6 months ] [ Designated as safety issue: No ]Wall motion score index in both the Reducer and control groups at baseline and six-month post-procedural evaluation
- Seattle Angina Questionnaire Score [ Time Frame: 6 months ] [ Designated as safety issue: No ]Seattle Angina Questionnaire in the Reducer and Control groups at baseline and six-month post-procedural evaluation
- Exercise Tolerance Testing [ Time Frame: 6 months ] [ Designated as safety issue: No ]Exercise Tolerance Testing in the Reducer and Control groups at baseline and six-month post-procedural evaluation
| Estimated Enrollment: | 124 |
| Study Start Date: | September 2010 |
| Estimated Study Completion Date: | October 2013 |
| Estimated Primary Completion Date: | April 2013 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: Reducer
Implant Reducer
|
Device: Neovasc Reducer
Implantation of the Reducer
|
|
Sham Comparator: Control
No treatment
|
Device: Control
Control - No device implanted
|
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Patient is older than 18 years of age
- Symptomatic CAD with chronic refractory angina pectoris classified as Canadian Cardiovascular Society grade III or IV despite attempted optimal medical therapy for thirty days prior to screening
- Patient has limited treatment options for revascularization by coronary artery bypass grafting or by percutaneous coronary intervention
- Evidence of reversible ischemia that is attributable to the left coronary arterial system
- At least 1 mm ST-segment depression at baseline exercise testing
- Left ventricular ejection fraction greater than 25%
- Male or non-pregnant female (NB: Females of child bearing potential must have a negative pregnancy test)
- Patient understands the nature of the procedure and provides written informed consent prior to enrollment
- Patient is willing to comply with specified follow-up evaluation and can be contacted by telephone
Exclusion Criteria:
- Recent (within three months) acute coronary syndrome
- Recent (within six months) successful PCI or CABG
- Unstable angina (recent onset angina, crescendo angina, or rest angina with ECG changes) during the thirty days prior to screening
- De-compensated congestive heart failure (CHF) or hospitalization due to CHF during the three months prior to screening
- Life threatening rhythm disorders or any rhythm disorders that would require placement of an internal defibrillator and or pacemaker
- Severe chronic obstructive pulmonary disease (COPD) as indicated by a forced expiratory volume in one second that is less than 55% of the predicted value
- Patient cannot undergo exercise tolerance test (bicycle) for reasons other than refractory angina
- Severe valvular heart disease
- Patient with pacemaker or defibrillator electrode in the right atrium, right ventricle, or coronary sinus
- Patient having undergone tricuspid valve replacement or repair
- Chronic renal failure (serum creatinine >2 mg/dL), including patients on chronic hemodialysis
- Moribund patients, or patients with comorbidities limiting life expectancy to less than one year
- Contraindication to required study medications that cannot be adequately controlled with pre-medication
- Known allergy to stainless steel or nickel
- Contraindication to having an MRI performed (NB: Cardiac MRI subset patients only)
- Currently enrolled in another investigational device or drug trial that has not completed the primary endpoint or that clinically interferes with the current study endpoints
- Mean right atrial pressure higher than or equal to 15 mmHg
- Patient with anomalous or abnormal CS as demonstrated by angiogram. Abnormality defined as:
Abnormal CS anatomy (e.g., tortuosity, aberrant branch, persistent left SVC) and/or; CS diameter at the site of planned reducer implantation less than 9.5 mm or greater than 13 mm
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01205893
Contacts
| Contact: Stefan Verheye, MD | +32(3)2803255 | stefan.verheye@zna.be |
Locations
| Belgium | |
| ZNA Middelheim Hospital | Recruiting |
| Antwerpen, Belgium, 2020 | |
| Contact: Stefan Verheye, MD +32(3)2803255 stefan.verhey@zna.be | |
| Principal Investigator: Stefan Verheye, MD | |
| Ziekenhuis Oost-Limburg | Recruiting |
| Genk, Belgium, 3600 | |
| Contact: Mathias Vrolix, MD 089 32 5050 Mathias.Vrolix@zol.be | |
| Principal Investigator: Mathias Vrolix, MD | |
| Canada, Ontario | |
| Ottawa Heart Institute | Recruiting |
| Ottawa, Ontario, Canada, K1Y 4W7 | |
| Contact: Marino Labinaz, MD (613) 761-5427 mlabinaz@ottawaheart.ca | |
| Principal Investigator: Marino Labinaz, MD | |
| Canada, Quebec | |
| Montreal Heart Institute | Recruiting |
| Montreal, Quebec, Canada, H1T 1C8 | |
| Contact: Marc Jolicoeur 514-376-3330 ext 3249 Marc.Jolicoeur@icm-mhi.org | |
| Principal Investigator: Marc Jolicoeur, MD | |
| Denmark | |
| Rigshospitalet | Recruiting |
| Copenhagen, Denmark, DK-2100 | |
| Contact: Thomas Engstrom, MD 45 35 45 11 91 thomas.engstroem@rh.regionh.dk | |
| Principal Investigator: Thomas Enstrom, MD | |
| Netherlands | |
| UMC Utrecht | Recruiting |
| Utrecht, Netherlands, 3584 | |
| Contact: Pierfracesco Agostoni, MD 31-88-7556167 p.agostoni@umcutrecht.nl | |
| Principal Investigator: Pierfrancesco Agostoni, MD | |
| Sweden | |
| Central Hospital Kristianstad | Recruiting |
| Kristianstad, Sweden, 85 | |
| Contact: Thomas Pettersson, MD 46443091441 Thomas.Pettersson@skane.se | |
| Principal Investigator: Thomas Petterson, MD | |
| United Kingdom | |
| Royal Infirmary of Bradford | Recruiting |
| Bradford, United Kingdom | |
| Contact: Paul Sainsbury, MD +447909830411 sainsburypaul@yahoo.co.uk | |
| Principal Investigator: Paul Sainsbury, MD | |
| Royal Infirmary of Edinburgh | Recruiting |
| Edinburgh, United Kingdom, EH16 4SA | |
| Contact: Neal Uren, MD 44 131 242 1842 | |
| Principal Investigator: Neal Uren, MD | |
| King College Hospital | Recruiting |
| London, United Kingdom, SE5 9RS | |
| Contact: Jonathan Hill, MD +44 203 2995945 jmhill@nhs.net | |
| Principal Investigator: Jonathan Hill, MD | |
| Royal Brompton Hospital | Recruiting |
| London, United Kingdom, SW3 6NP | |
| Contact: Ranil deSilva, MRCP PhD 442073518298 r.desilva@imperial.ac.uk | |
| Principal Investigator: Ranil deSilva, MRCP PhD | |
Sponsors and Collaborators
Neovasc Inc.
Investigators
| Principal Investigator: | Stefan Verheye, MD | ZNA Middelheim Hospital |
More Information
No publications provided by Neovasc Inc.
Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | Neovasc Inc. |
| ClinicalTrials.gov Identifier: | NCT01205893 History of Changes |
| Other Study ID Numbers: | #REDCLN-178 |
| Study First Received: | September 13, 2010 |
| Last Updated: | November 14, 2012 |
| Health Authority: | Belgium: Ethics Committee Belgium: Ministry of Social Affairs, Public Health and the Environment |
Additional relevant MeSH terms:
|
Angina Pectoris Myocardial Ischemia Heart Diseases Cardiovascular Diseases |
Vascular Diseases Chest Pain Pain Signs and Symptoms |
ClinicalTrials.gov processed this record on May 16, 2013